David Posner, MD
Pulmonary Disease · New York, NYNPI 1982794848
Payments from drug & device makers
Across 658 payments — averaging $20.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$3K
- Boehringer Ingelheim$2K
- Insmed, Inc.$965
- Regeneron Healthcare Solutions, Inc.$930
- Sanofi$654
- plus $3K from 24 others
What the payments were for
- Food & beverage$13,15498%
- Education$2702%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 148 | $3,133 |
| GSK | 186 | $2,855 |
| Boehringer Ingelheim | 65 | $1,635 |
| Insmed, Inc. | 51 | $965 |
| Regeneron Healthcare Solutions, Inc. | 38 | $930 |
| Sanofi | 26 | $654 |
| Mylan Specialty L.p. | 27 | $596 |
| Mallinckrodt Hospital Products Inc. | 14 | $502 |
| Amgen | 20 | $465 |
| Genentech USA, Inc. | 20 | $302 |
| Electromed, Inc. | 8 | $177 |
| Novartis | 7 | $152 |
| Baxter Healthcare | 4 | $137 |
| Teva Pharmaceuticals USA, Inc. | 7 | $130 |
| Verona Pharma, Inc. | 4 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $116 |
| Advanced Respiratory, Inc | 5 | $93 |
| Sunovion Pharmaceuticals Inc. | 4 | $73 |
| Paratek Pharmaceuticals, Inc. | 3 | $60 |
| ANI Pharmaceuticals, Inc. | 2 | $59 |
| Philips North America LLC | 2 | $43 |
| Merck | 2 | $39 |
| Amarin Pharma, Inc. | 2 | $35 |
| Pfizer | 2 | $33 |
| United Therapeutics Corporation | 2 | $27 |
| AbbVie | 1 | $24 |
| Eisai Inc. | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Circassia Inc. | 1 | $12 |
How this compares
$13,424 in reported general payments places this provider in the 80th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 39 | $723,750 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 189 | $156,802 |
| Pirfenidone | 19 | $99,882 |
| Dupixent PenDupilumab | 20 | $91,185 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 140 | $91,069 |
| Fasenra PenBenralizumab | 16 | $90,992 |
| Breo ElliptaFluticasone/Vilanterol | 145 | $74,657 |
| Spiriva RespimatTiotropium Bromide | 32 | $32,750 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 37 | $27,283 |
| Incruse ElliptaUmeclidinium Bromide | 34 | $20,527 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $17,808 |
| SymbicortBudesonide/Formoterol Fumarate | 49 | $16,877 |
| Arnuity ElliptaFluticasone Furoate | 50 | $14,595 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 76 | $13,037 |
| Spiriva HandihalerTiotropium Bromide | 18 | $11,710 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $1,635 | $783,782108 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $2,855 | $357,650558 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,133 | $34,68578 claims |
| MerckDulera | $39 | $8,40916 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $130 | $5,94814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in New York
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Doreen Addrizzo-HarrisNew York$1.9M
- Emily DimangoNew York$1.4M
- da ZhangNew York$1.3M
- Claire KeatingNew York$1.2M
- Charles PowellNew York$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.